RecruitingNCT06022328

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Bordeaux
Intervention
Assessment of the epigenetic age(biological)
Enrollment
120 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06022328 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm →

← Back to all trials